Qnovia, Inc. announces FDA clearance of IND application for lead asset RespiRx™ Nicotine Inhaler as a prescription smoking cessation therapy ...Middle East

- Phase 1 clinical trial for smoking cessation expected to dose first patient in 4Q 2024 - - The study will evaluate the pharmacokinetics, safety and tolerability of the RespiRx™ Nicotine Inhaler compared to Nicotrol® Inhaler and combustible cigarettes - RICHMOND, Va., Oct. 1, 2024...

Read More Details
Finally We wish PressBee provided you with enough information of ( Qnovia, Inc. announces FDA clearance of IND application for lead asset RespiRx™ Nicotine Inhaler as a prescription smoking cessation therapy )

Also on site :

• AB Anywhere: Why List on Binance Alpha?
• Egypt’s tourism sees 25% surge in early 2025, defying regional challenges
• The 5 most affordable states in America — and the 5 least affordable